Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebselen - Sound Pharmaceuticals

Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Medical University of South Carolina; Nattermann; Sound Pharmaceuticals; University of Oxford
  • Class Antiulcers; Azoles; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar disorders; Hearing loss; Meniere's disease; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 14 Jan 2019 Phase-II clinical trials in Hearing loss in USA (PO) (NCT02819856)
  • 24 Jun 2018 Biomarkers information updated
  • 10 Oct 2017 University of Oxford, Stanley Medical Research Institute and Sound Pharmaceuticals plans a phase II trial for Bipolar disorders in United Kingdom (PO) in October 2017 (NCT03013400) (EudraCT2015-000323-86)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top